New injectable pharmaceutical drugs both prevent and cure HIV infections


Researchers have developed an injectable peptide-based drug which prevents HIV from infecting cells. The novel therapy provides long-lasting safety, and has few side effects, unlike other medications available on the market. Experiments on non-human primates have found that, although the virus is already present, the drug can be used to significantly decrease the amount of HIV circulating in the bloodstream. Pre-exposure prophylaxis (or PrEP) is a way for people who do not have HIV but are at very high risk of contracting HIV by taking a pill every day to avoid HIV infection. The pill (brand name Truvada) contains two drugs (tenofovir and emtricitabine) which are used to treat HIV in combination with other drugs. PrEP is highly effective in combating HIV, when taken regularly. Reports have shown that when taken regularly, PrEP decreases the risk of sex-related HIV by around 99 per cent. PrEP decreases the chance of developing HIV by at least 74 per cent of people who inject drugs when taken regularly. PrEP is far less effective when not consistently taken. Currently there are over 38 million people living with the infection. Fortunately, these people can now take advanced antiretroviral therapy (cART), a drug cocktail that dramatically enhances survivability and prevents AIDS from beginning. HIV medications also prevent individuals with the virus from passing it on to their partner during pregnancy. Proteins and peptides that exist most naturally in the L-configuration are composed of amino acids. D-peptides are basically the L-peptides mirror form, kind of like your left and right hand — they're exactly the same, but in different configurations. Because D-peptides are so similar to natural peptides, the immune system generally lacks them, avoiding unnecessary immune reactions, which are often a side effect of conventional HIV medications. In addition, CPT31 lasts longer in the body compared to natural peptides, making them particularly suitable for injectable formulations that take long-acting action. This review tells about the future scope of the new invention towards the field of HIV /AIDS and their medicinal treatment. People who are interested can send their article towards our journal for publication through this